Evolved Biochromatography Media CIM Monolith Column

Participation in this webinar has ended. If you wish to view it, please contact us. We will send you the URL for the recorded video at a later date. AAV-based gene therapy is widely accepted and recognized in the biopharmaceutical industry. However, there are still challenges to address in order to manufacture affordable and safe AAV-based products with robust purification processes that are easy to scale up in downstream process development. In this webinar, we will explain how Sartorius can assist you in developing scalable and robust downstream purification processes for AAV using the Monolith provided by Sartorius. AAV Webinar Series 1 is here: https://srtrs.info/ios9v *We apologize, but participation from companies in the same industry and from email addresses other than those of your organization is not permitted. Thank you for your understanding.

Participation in this webinar has ended. If you wish to view it, please contact us. We will send you the URL for the recorded video at a later date. During the COVID-19 pandemic, mRNA-based vaccines have been widely recognized by the biopharmaceutical industry and regulatory authorities. However, in downstream process development, there are challenges to address in order to manufacture affordable and safe mRNA-based vaccines using scalable and robust purification processes. We aim to introduce solutions that can be provided using our CIM monolith and develop a scalable and robust downstream purification process from pDNA to mRNA. ▪ Method of holding: Webinar recorded broadcast [in Japanese, free of charge] *We sincerely apologize, but participation from individuals using email addresses other than those from your company or organization is not permitted. Thank you for your understanding.

Participation in this webinar has ended. If you wish to view it, please contact us, and we will send you the URL for the recorded video at a later date. In recent years, the rapid spread of mRNA vaccines has suddenly drawn attention to this field, but it seems that a standardized platform has yet to be established. In this webinar, we will particularly address two key points—IVT and purification—through our company's new solution-based approach. 【Main Learning Content】 ▪ Current status and challenges of mRNA pharmaceutical manufacturing processes ▪ Revolutionary purification column (Monolith) ▪ Diverse process development approaches *We kindly ask that inquiries be made using email addresses from your company or organization, as we regretfully cannot accommodate inquiries from other email addresses. Thank you for your understanding.

Participation in this webinar has ended. Those who wish to view it on demand can register through the details and application section. mRNA vaccines play a crucial role in combating SARS-CoV-2, and the need to produce mRNA has never been greater due to the ongoing development of treatments for various indications. In this three-part webinar series, Sartorius experts will explain how improvements in processes, analytics, and tools are key to meeting demand. Part 1 will explore the processes, analytics, and tools needed to meet the high demand for mRNA, starting with the production of pDNA. We will introduce methods to achieve high yields of pDNA by ensuring the quality and purity of raw materials and optimizing the manufacturing process. [Topics] ▪ Examination of strategies to minimize contamination from product-derived impurities in IVT reactions ▪ Introduction of ready-to-use solutions for scalable pDNA chromatography purification ▪ Verification of the actual effectiveness of the HiP2 Plasmid Process Pack for purifying linearized pDNA